Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 48

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 48
---
 is recorded, processed, summarized
and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated
to management, including our Principal Executive Officer and Interim Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosure.

We
recognize that any controls system, no matter how well designed and operated, can provide only reasonable assurance of achieving its objectives,
and our management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control over Financial
Reporting

There
were no changes in our internal control over financial reporting during the period covered by this quarterly report that materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)
under the Exchange Act).

35

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party
to any pending legal proceedings that we believe will have a material adverse effect on our business or financial conditions. We may,
however, be subject to various claims and legal actions arising in the ordinary course of business from time to time.

Item 1A. Risk Factors

Not required for smaller reporting
companies. 

Item 2. Recent Sales of
Unregistered Securities; Use of Proceeds from Registered Securities

None.

Item 3. Defaults Upon
Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Severance Agreement 

On August 4, 2025, Dr. Raymond
J. Tesi informed the Company of his intention to retire and resign from his roles as President, Chief Executive Officer, Chief Medical
Officer, Chairman of the Board of Directors (the “Board”) and all positions from the Company and its subsidiaries, effective
on the Effective Date (as defined below). Dr. Tesi’s resignation is not the result of any dispute or disagreement with the Company
or the Board on any matter relating to the Company’s operations, policies or practices.

36

In connection with Dr. Tesi’s
retirement, Dr. Tesi and the Company entered into a Separation Agreement and Mutual Release, dated August 4, 2025 (the “Severance
Agreement”), pursuant to which, in exchange for a general release of claims and other customary terms, the Company agreed to provide
Dr. Tesi with a